AI-Assisted Implant Planning Using CBCT Data (AIP-CBCT)

May 13, 2026 updated by: St. Petersburg State Pavlov Medical University

Retrospective Reader Study of AI-Assisted Implant Planning Using Cone-Beam Computed Tomography Data in Edentulous Patients

This retrospective observational reader study will evaluate artificial intelligence (AI)-assisted implant planning using anonymized cone-beam computed tomography (CBCT) datasets from patients with complete edentulism or a clinically equivalent edentulous condition. AI-generated implant plans will be compared with expert reference plans created by clinicians using the same CBCT data. The study will assess the clinical acceptability of AI-generated implant plans, geometric agreement with expert plans, anatomical safety, workflow time, and agreement between expert reviewers where applicable. The study uses previously acquired anonymized imaging data and does not involve patient recruitment, treatment allocation, additional imaging, clinical intervention, or prospective follow-up.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is designed as a retrospective non-randomized comparative reader study. Anonymized CBCT datasets acquired during routine clinical care will be used for implant planning assessment. For each eligible case, expert clinicians will create reference implant plans without access to AI-generated plans. The AI system will generate implant planning outputs from the same CBCT datasets, and expert clinicians will review the AI-generated plans using a standardized assessment approach. The main evaluation will compare AI-generated plans with expert reference plans within the same case. Outcomes will include clinical acceptability of the AI-generated plan, geometric agreement between AI-generated and expert plans, anatomical safety relative to relevant risk structures, time required for expert planning versus AI-plan review and correction, and inter-reader agreement where applicable. The study does not test an autonomous AI decision-making system. The AI workflow is evaluated as a clinical decision-support tool, and all AI-generated plans are subject to expert clinician review. No new imaging examinations, treatment allocation, patient intervention, or prospective clinical outcome assessment will be performed.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Russia
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Russia, 197022
        • Pavlov First Saint Petersburg State Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population will consist of anonymized CBCT cases from edentulous patients, or patients with a clinically equivalent edentulous condition, who underwent CBCT imaging during routine clinical care for implant prosthodontic planning. No new patient recruitment, additional imaging, treatment allocation, or patient intervention will be performed.

Description

Inclusion Criteria:

  • Anonymized CBCT dataset from a patient with complete edentulism or a clinically equivalent edentulous condition requiring implant prosthodontic planning.
  • CBCT imaging acquired during routine clinical care.
  • Sufficient field of view to assess the jaws and relevant anatomical landmarks for implant planning.
  • Image quality sufficient for anatomical assessment, segmentation, and implant planning.
  • Technical suitability of the CBCT dataset for expert reference planning and AI-assisted implant planning.

Exclusion Criteria:

  • Severe motion artifacts or metal artifacts preventing reliable anatomical assessment.
  • Incomplete field of view preventing assessment of the intended implant planning region.
  • Corrupted, incomplete, duplicate, or unreadable DICOM data.
  • Technical limitations preventing expert reference planning or AI-assisted implant planning.
  • Missing data required for assessment of the primary outcome.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Retrospective CBCT Planning Cases
Anonymized cone-beam computed tomography (CBCT) cases from patients with complete edentulism or a clinically equivalent edentulous condition who underwent CBCT imaging for implant planning during routine clinical care. Each case will be evaluated using expert reference planning and AI-assisted implant planning with expert review.
Other: AI-Assisted Implant Planning Workflow
AI-assisted implant planning workflow applied to anonymized CBCT datasets. The workflow generates implant planning outputs for expert review and comparison with expert reference plans. It is evaluated as a clinical decision-support workflow and does not involve patient treatment, additional imaging, or autonomous clinical decision-making.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Clinical acceptability of AI-generated implant plans
Time Frame: Baseline
Proportion of AI-generated implant plans rated by expert clinicians as accepted without modification, accepted after minor modification, accepted after major modification, or rejected.
Baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Geometric agreement between AI-generated and expert reference implant plans
Time Frame: Baseline
Geometric agreement will be assessed for matched implants using entry-point deviation, apical deviation, and angular deviation between AI-generated and expert reference implant positions.
Baseline
Anatomical safety of AI-generated implant plans
Time Frame: Baseline
Anatomical safety will be assessed using minimum distances from planned implants to relevant anatomical risk structures and the presence or absence of predefined safe-margin violations.
Baseline
Workflow time for AI-assisted planning review compared with expert planning
Time Frame: Baseline
Time required for independent expert implant planning will be compared with the time required for expert review and correction of AI-generated implant plans.
Baseline
Inter-reader agreement for clinical acceptability ratings
Time Frame: Baseline
Agreement between expert clinicians will be assessed for clinical acceptability ratings of AI-generated implant plans where more than one expert evaluates the same cases.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
St. Petersburg State Pavlov Medical University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Roman A Rozov, MD, DSc, St. Petersburg State Pavlov Medical University
  • Study Director: Karina Sh Oisieva, DDS, MSc, Saint Petersburg State University, Russia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 16, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 30, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 30, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 8, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 13, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 19, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 19, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 13, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • LEC-05-26-N

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared because the study uses retrospective anonymized medical imaging datasets. CBCT/DICOM data may contain potentially re-identifiable information and cannot be publicly shared. Aggregated results will be reported in publications.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings